COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant
14 May 2021
For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
13 May 2021
Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
6 May 2021
Andrew Pollard writes about vaccine equity in his article for The Conversation.
29 April 2021
Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.
14 April 2021
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
14 April 2021
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
1 April 2021
The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
22 March 2021
Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall. Vaccine 100% effective against severe or critical symptomatic COVID-19. No safety concerns reported
19 March 2021
Samantha Vanderslott, Andrew Pollard and Seilesh Kadambari discuss vaccine uptake among Black, Asian and minority ethnic communities in an article for The Conversation.
Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
24 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
13 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
11 February 2021
WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.
4 February 2021
The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
27 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
7 January 2021
Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.
17 December 2020
Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.